ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing Post author:andrewkaretas Post published:December 17, 2021 Post category:CD19/Scientific Publications Continue ReadingALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing
Safety and PK/PD of ALLO-647, an Anti-CD52 Antibody, With Fludarabine (Flu)/Cyclophosphamide (Cy) for Lymphodepletion in Allogeneic CAR T Cell Therapy Post author:andrewkaretas Post published:June 18, 2021 Post category:ALLO-647/Scientific Publications Continue ReadingSafety and PK/PD of ALLO-647, an Anti-CD52 Antibody, With Fludarabine (Flu)/Cyclophosphamide (Cy) for Lymphodepletion in Allogeneic CAR T Cell Therapy
First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study Post author:andrewkaretas Post published:June 1, 2021 Post category:CD19/Scientific Publications Continue ReadingFirst-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study
PD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:April 18, 2021 Post category:PLATFORM/Scientific Publications Continue ReadingPD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs
Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma Post author:andrewkaretas Post published:December 22, 2020 Post category:BCMA/Scientific Publications Continue ReadingPreclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma
Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML Post author:andrewkaretas Post published:December 18, 2020 Post category:CD70/Scientific Publications Continue ReadingInvestigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML
First-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study) Post author:andrewkaretas Post published:December 9, 2020 Post category:BCMA/Scientific Publications Continue ReadingFirst-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery Post author:andrewkaretas Post published:October 18, 2020 Post category:FLT3/Scientific Publications Continue ReadingAllogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
American Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:June 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs
American Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer Post author:andrewkaretas Post published:June 18, 2020 Post category:DLL3/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer
